SCHEMBL4859940

SCHEMBL4859940

CCOC(=O)COc1ccc(N(C)C(=O)OC(C)(C)C)cc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.41
LMNA P02545 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TSHR P16473 1/20 0.38
RXRA P19793 2/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
THRA P10827 1/20 0.36
THRB P10828 1/20 0.36
AAK1 Q2M2I8 1/20 0.36
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
AR P10275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859374 0.89 AR (0.41) LMNAKDM4EALDH1A1MEN1KMT2A
SCHEMBL4861398 0.87 ESR1 (0.42) ESR1LMNAKDM4EALDH1A1MAPK1
SCHEMBL4861312 0.86 ESR1 (0.52) ESR1LMNAKDM4EALDH1A1MAPK1
SCHEMBL4860564 0.84 ALDH1A1 (0.53) ESR1ALDH1A1KMT2ATSHR
SCHEMBL4860648 0.84 ALDH1A1 (0.46) ESR1KDM4EALDH1A1MAPK1MEN1
SCHEMBL1549489 0.79 ESR1 (0.38) ESR1ALDH1A1MAPK1MEN1KMT2A
SCHEMBL4851692 0.78 S1PR1 (0.45) LMNAKDM4EGLAMAPK1MEN1
SCHEMBL5323264 0.77 ESR1 (0.50) ESR1KDM4EGLAALDH1A1MAPK1
SCHEMBL4859929 0.76 POLB (0.46) ESR1KDM4EGLAALDH1A1MAPK1
SCHEMBL1549433 0.76 POLB (0.42) ESR1LMNAKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345067-B2 Aniline derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2008-03-18 US disclosed
EP-1636198-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-22 EP disclosed
WO-2004111020-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-12-23 WO disclosed
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals PPARA, PPARD, PPARG ESR1 1044/4885LMNA 1382/4885KDM4E 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.